| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01017 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C11D3-38681
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C11D3-386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-189
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2462
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C11D3-48 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C11D3-386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 |
| filingDate |
2020-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f45fd8ed8c72b88e44b363d62a00ec6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8e810c9e18deabdb49703bab575471f |
| publicationDate |
2022-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022228135-A1 |
| titleOfInvention |
Chimeric endolysin lys109 with antimicrobial activity against staphylococcus aureus |
| abstract |
The present invention relates to chimeric endolysin Lys109 which effectively controls Staphylococcus aureus , wherein the endolysin Lys109 of the present invention has a novel amino acid sequence that has not been conventionally studied. Endolysin Lys109 of the present invention can be used as a biological regulator capable of effectively inhibiting a wide range of Staphylococcus aureus and a biofilm produced thereby. In addition, endolysin Lys109 can kill Staphylococcus aureus without regard for resistance to conventional antibiotics, and thus can be widely used for treatment of diseases caused by Staphylococcus aureus infection. Moreover, endolysin Lys109 can also be used to resolve medical problems caused by Staphylococcus aureus which has antibiotic resistance. |
| priorityDate |
2019-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |